152 related articles for article (PubMed ID: 35131879)
1. Clinical Performance of the BD Onclarity Extended Genotyping Assay for the Management of Women Positive for Human Papillomavirus in Cervical Cancer Screening.
Volesky KD; Magnan S; Mayrand MH; Isidean SD; El-Zein M; Comète E; Franco EL; Coutlée F
Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):851-857. PubMed ID: 35131879
[TBL] [Abstract][Full Text] [Related]
2. Machine Learning Interpretation of Extended Human Papillomavirus Genotyping by Onclarity in an Asian Cervical Cancer Screening Population.
Wong OGW; Ng IFY; Tsun OKL; Pang HH; Ip PPC; Cheung ANY
J Clin Microbiol; 2019 Dec; 57(12):. PubMed ID: 31511337
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.
Song F; Du H; Wang C; Huang X; Wu R;
PLoS One; 2020; 15(6):e0234518. PubMed ID: 32525936
[TBL] [Abstract][Full Text] [Related]
4. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
[TBL] [Abstract][Full Text] [Related]
5. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: A retrospective study of 8726 cases.
Tao X; Zhang H; Zhang H; Xiao Y; Zhong F; Zhou X; Cong Q; Sui L; Zhao C
Cancer Cytopathol; 2022 Jul; 130(7):542-550. PubMed ID: 35312217
[TBL] [Abstract][Full Text] [Related]
6. Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial.
Stoler MH; Wright TC; Parvu V; Yanson K; Cooper CK; Andrews JA
Gynecol Oncol; 2023 Mar; 170():143-152. PubMed ID: 36682092
[TBL] [Abstract][Full Text] [Related]
7. Extended Human Papillomavirus Genotyping to Predict Progression to High-Grade Cervical Precancer: A Prospective Cohort Study in the Southeastern United States.
Bukowski A; Hoyo C; Hudgens MG; Brewster WR; Valea F; Bentley RC; Vidal AC; Maguire RL; Schmitt JW; Murphy SK; North KE; Smith JS
Cancer Epidemiol Biomarkers Prev; 2022 Aug; 31(8):1564-1571. PubMed ID: 35654413
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial.
Stoler MH; Parvu V; Yanson K; Andrews J; Vaughan L
Gynecol Oncol; 2023 Jul; 174():68-75. PubMed ID: 37149907
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation testing with S5 for triage of high-risk HPV positive women.
Adcock R; Nedjai B; Lorincz AT; Scibior-Bentkowska D; Banwait R; Torrez-Martinez N; Robertson M; Cuzick J; Wheeler CM;
Int J Cancer; 2022 Oct; 151(7):993-1004. PubMed ID: 35477862
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness of human papillomavirus load, reflected by cycle threshold values, for the triage of HPV-positive self-samples in cervical cancer screening.
Song F; Du H; Wang C; Huang X; Qu X; Wei L; Belinson JL; Wu R;
J Med Screen; 2021 Sep; 28(3):318-324. PubMed ID: 32869705
[TBL] [Abstract][Full Text] [Related]
11. p16/Ki67 dual stain triage versus cytology in primary human papillomavirus-based cervical cancer screening with limited genotyping.
Trzeszcz M; Mazurec M; Jach R; Mazurec K; Kotkowska-Szeps I; Kania M; Wantuchowicz M; Wasowska J; Duczek-Polakiewicz M; Rozmus P; Streb J; Halon A
J Med Virol; 2023 Nov; 95(11):e29271. PubMed ID: 38009626
[TBL] [Abstract][Full Text] [Related]
12. The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples.
Ebisch RM; de Kuyper-de Ridder GM; Bosgraaf RP; Massuger LF; IntHout J; Verhoef VM; Heideman DA; Snijders PJ; Meijer CJ; van Kemenade FJ; Bulten J; Siebers AG; Bekkers RL; Melchers WJ
Int J Cancer; 2016 Aug; 139(3):691-9. PubMed ID: 26991464
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of partial genotyping with HPV16/18 for triage of HPV positive, cytology negative women in the COMPACT study.
Hanley SJB; Fujita H; Aoyama-Kikawa S; Kasamo M; Torigoe T; Matsuno Y; Noriaki S;
J Gynecol Oncol; 2021 Nov; 32(6):e86. PubMed ID: 34708593
[TBL] [Abstract][Full Text] [Related]
14. Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology.
Stoler MH; Wright TC; Parvu V; Yanson K; Cooper CK; Andrews J
Gynecol Oncol; 2019 Apr; 153(1):26-33. PubMed ID: 30638767
[TBL] [Abstract][Full Text] [Related]
15. Clinical Performance of hrHPV Primary Screening Using Vaginal versus Cervical Samples to Detect High-grade Intraepithelial Lesions.
King J; Flores YN; Meneses-León J; Hernández-Salazar S; Robles-Rivera K; Rivera-Paredez B; León-Maldonado L; Hernández-López R; Torres-Ibarra L; Lazcano-Ponce E; Salmerón J
Cancer Prev Res (Phila); 2023 Dec; 16(12):681-687. PubMed ID: 37788346
[TBL] [Abstract][Full Text] [Related]
16. HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology.
Stoler MH; Wright TC; Parvu V; Yanson K; Eckert K; Kodsi S; Cooper C
Am J Clin Pathol; 2019 Mar; 151(4):433-442. PubMed ID: 30649177
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study.
Dong L; Wang MZ; Zhao XL; Feng RM; Hu SY; Zhang Q; Smith JS; Qiao YL; Zhao FH
Gynecol Oncol; 2018 Jan; 148(1):103-110. PubMed ID: 29169614
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
Xu L; Oštrbenk A; Poljak M; Arbyn M
J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan.
Chang CL; Ho SC; Su YF; Juan YC; Huang CY; Chao AS; Hsu ZS; Chang CF; Fwu CW; Chang TC
Gynecol Oncol; 2021 May; 161(2):429-435. PubMed ID: 33757653
[TBL] [Abstract][Full Text] [Related]
20. Comparing the performance of 2 human papillomavirus assays for a new use indication: a real-world evidence-based evaluation in the United States.
Wheeler CM; Torrez-Martinez NE; Torres-Chavolla E; Parvu V; Andrews JC; Du R; Robertson M; Joste NE; Cuzick J;
Am J Obstet Gynecol; 2024 Feb; 230(2):243.e1-243.e11. PubMed ID: 37806613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
